

Kim A Margolin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4908279/kim-a-margolin-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

189
papers

17,198
citations

57
h-index

130
g-index

206
ext. papers

19,934
ext. citations

7.4
avg, IF

6.13
L-index

#	Paper	IF	Citations
189	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. <i>Lancet Oncology, The</i> , 2021 , 22, 1692-1704	21.7	23
188	Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021 , 23, 356-375	1	28
187	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). <i>Neuro-Oncology</i> , 2021 , 23, 1961-1973	19.7	24
186	Pathologic complete response with radiation and vismodegib in a patient with advanced basal cell carcinoma: A case report. <i>Molecular and Clinical Oncology</i> , 2021 , 14, 46	1.6	3
185	Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature. <i>SAGE Open Medical Case Reports</i> , 2021 , 9, 20503133X211042215	0.7	1
184	Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. <i>ESMO Open</i> , 2021 , 6, 100252	6	6
183	Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma. <i>JAAD Case Reports</i> , 2020 , 6, 195-197	1.4	7
182	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. <i>Pigment Cell and Melanoma Research</i> , 2020 , 33, 527-541	4.5	21
181	Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy 2020 , 1421-1454		
180	NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 120-131	7.3	3
179	A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. <i>Cell</i> , 2020 , 183, 347-362.e24	56.2	128
178	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. <i>JAMA Oncology</i> , 2020 , 6, 1256-1264	13.4	27
177	Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling. <i>Annals of Surgical Oncology</i> , 2020 , 27, 5240-5247	3.1	1
176	And Now for Something Completely Different: Immunotherapy Beyond Checkpoints in Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020 , 40, 1-12	7.1	
175	Cytokine Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2019 , 33, 261-274	3.1	9
174	Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, e59-e69	7.1	6
173	Fulminant Disseminated Intravascular Coagulation as Initial Presentation of BRAF-Mutated Melanoma. <i>Case Reports in Oncological Medicine</i> , 2019 , 2019, 9246596	0.9	1

172	Metabolic Checkpoint of Immune Cells in Melanoma Brain Metastases. <i>Cancer Discovery</i> , 2019 , 9, 581-583	4.4	0
171	Reply to A. Shinde et al. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1031-1032	2.2	
170	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2019 , 37, 693-702	2.2	188
169	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , 2019 , 20, e378-e389	21.7	88
168	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2019 , 32, 458-469	4.5	15
167	High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. <i>Frontiers in Oncology</i> , 2019 , 9, 1483	5.3	6
166	Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy 2019 , 1-34		
165	What is new on the horizon in melanoma brain metastasis?. <i>ESMO Open</i> , 2019 , 4, e000579	6	2
164	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. <i>Cancer</i> , 2019 , 125, 18-44	6.4	15
163	Management of Metastatic Melanoma in 2018. <i>JAMA Oncology</i> , 2018 , 4, 857-858	13.4	22
162	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology</i> , 2018 , 19, e20-e32	21.7	63
161	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0 2018 , 6, 44		39
160	Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018 , 24, 5552-5561	12.9	89
159	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018 , 379, 722-730	59.2	659
158	Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018 , 379, 2178	59.2	11
157	NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. <i>Cancer</i> , 2018 , 124, 4332-4341	6.4	5
156	Human breast tumor-infiltrating CD8 T cells retain polyfunctionality despite PD-1 expression. <i>Nature Communications</i> , 2018 , 9, 4297	17.4	48
155	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). <i>Clinical Cancer Research</i> , 2017 , 23, 5034-5043	12.9	24

154	A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). <i>Cancer</i> , 2017 , 123, 2688-2697	6.4	69
153	Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 641-650	7.1	6
152	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , 2017 , 86, 37-45	7.5	106
151	Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 641-650	7.1	5
150	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016 , 29, 627-642	4.5	74
149	Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. <i>Journal of Experimental Medicine</i> , 2016 , 213, 1133-9	16.6	55
148	T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3787-3795	2.2	66
147	Updates in the management of brain metastases. <i>Neuro-Oncology</i> , 2016 , 18, 1043-65	1	158
146	Brain Metastases in Melanoma: Moving Toward Curing the Incurable. <i>Journal of Oncology Practice</i> , 2016 , 12, 545-6	3.1	2
145	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016 , 374, 2542-52	59.2	828
144	Treatment of Renal Cell Cancer With Programmed Cell Death 1 Blockade: How Much Is Enough?. <i>JAMA Oncology</i> , 2016 , 2, 1186-7	13.4	
143	The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma. <i>Current Treatment Options in Oncology</i> , 2016 , 17, 48	5.4	31
142	BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804). <i>Journal of Clinical Oncology</i> , 2015 , 33, 2384-91	2.2	63
141	Hemorrhagic collision metastasis in a cerebral arteriovenous malformation. <i>Journal of NeuroInterventional Surgery</i> , 2015 , 7, e34	7.8	6
140	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , 2015 , 16, 908-18	21.7	1151
139	Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. <i>Cancer</i> , 2015 , 121, 432-440	6.4	66
138	The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 561-8	12.9	114
137	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1889-94	2.2	1425

136	Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative	2.2	80
135	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015 , <i>33</i> , 1430-7	2.2	735
134	Response assessment criteria for brain metastases: proposal from the RANO group. <i>Lancet Oncology, The</i> , 2015 , <i>16</i> , e270-8	21.7	472
133	29th Annual meeting of the Society for Immunotherapy of Cancer (SITC) 2015 , <i>3</i> ,		9
132	Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2015 , <i>7</i> , 181-91	5.4	17
131	Immune checkpoint blockade in patients with melanoma metastatic to the brain. <i>Seminars in Oncology</i> , 2015 , <i>42</i> , 459-65	5.5	19
130	Effectiveness and safety of ipilimumab therapy in advanced melanoma: evidence from clinical practice sites in the US. <i>Journal of Community and Supportive Oncology</i> , 2015 , <i>13</i> , 131-138		4
129	Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , <i>13</i> , 811-22	7.3	9
128	Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. <i>Journal of Molecular Diagnostics</i> , 2014 , <i>16</i> , 56-67	5.1	203
127	Introduction to the role of the immune system in melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014 , <i>28</i> , 537-58	3.1	7
126	Kidney cancer, version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , <i>12</i> , 175-82	7.3	43
125	Hemorrhagic collision metastasis in a cerebral arteriovenous malformation. <i>BMJ Case Reports</i> , 2014 , <i>2014</i> ,	0.9	1
124	A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. <i>Cancer Journal (Sudbury, Mass)</i> , 2014 , <i>20</i> , 18-24	2.2	35
123	Medical Management of Melanoma 2014 , 651-660		
122	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. <i>Lancet Oncology, The</i> , 2013 , <i>14</i> , e396-406	21.7	92
121	Cytokines in the Treatment of Cancer 2013 , 173-210		
120	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. <i>Nature Reviews Clinical Oncology</i> , 2013 , <i>10</i> , 588-98	19.4	145
119	Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivors. <i>Clinical Genitourinary Cancer</i> , 2013 , <i>11</i> , 121-7	3.3	7

118	Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 399-403	7.1	16
117	Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases. <i>Expert Review of Dermatology</i> , 2013 , 8, 479-487		3
116	A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. <i>Journal of Immunotherapy</i> , 2013 , 36, 490-5	5	22
115	Multidisciplinary Approach to Brain Metastasis from Melanoma: The Emerging Role of Systemic Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 33, 393-398	7.1	15
114	Multidisciplinary Approach to Brain Metastasis from Melanoma; Local Therapies for Central Nervous System Metastases. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 33, 399-403	7.1	22
113	Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 393-8	7.1	21
112	A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. <i>Investigational New Drugs</i> , 2012 , 30, 741-8	4.3	51
111	BRAF inhibition and beyond in advanced melanoma. <i>Lancet, The</i> , 2012 , 380, 320-2	4.0	5
110	Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2012 , 13, 459-65	21.7	833
109	Ipilimumab in patients with melanoma and brain metastases [Authors Reply]. <i>Lancet Oncology, The</i> , 2012 , 13, e277-e278	21.7	3
108	Tumor-infiltrating lymphocytes in melanoma. <i>Current Oncology Reports</i> , 2012 , 14, 468-74	6.3	67
107	Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. <i>PLoS ONE</i> , 2012 , 7, e48787	3.7	60
106	Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 4592-7	11.5	127
105	An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer. <i>Cancer</i> , 2012 , 118, 4098-104	6.4	23
104	Ipilimumab in a Phase II trial of melanoma patients with brain metastases. <i>Oncology</i> , 2012 , 1, 1197-1199	7.2	35
103	Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). <i>Clinical Cancer Research</i> , 2012 , 18, 1129-37	12.9	68
102	Testicular cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 502-35	7.3	64
101	Targeting the mTOR, PI3K, and AKT Pathways in Melanoma 2012 , 107-123		

100	NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9 Suppl 1, S1-29	7.3	41
99	Kidney cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 960-77	7.3	79
98	A phase II trial of gefitinib and pegylated IFN α in previously treated renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2011 , 16, 494-9	4.2	9
97	Treatment of advanced melanoma with immunological checkpoint block. <i>Current Oncology Reports</i> , 2011 , 13, 430-2	6.3	2
96	Adoptive T-cell therapy of melanoma using designer T-cell receptors. <i>Current Oncology Reports</i> , 2011 , 13, 427-9	6.3	1
95	Aflibercept (VEGF Trap) in inoperable stage III or stage IV melanoma of cutaneous or uveal origin. <i>Clinical Cancer Research</i> , 2011 , 17, 6574-81	12.9	65
94	Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2178-84	2.2	161
93	Cytokines in cancer immunotherapy. <i>Cancers</i> , 2011 , 3, 3856-93	6.6	397
92	Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4906-11	2.2	202
91	Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1196-202	2.2	16
90	Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 927-33	3.5	8
89	Indoor tanning and substance-related disorder--related behaviors with similar treatment?. <i>Current Oncology Reports</i> , 2010 , 12, 288-9	6.3	
88	Indoor tanning use among U.S. youth--can skin health behaviors be legislated?. <i>Current Oncology Reports</i> , 2010 , 12, 290-1	6.3	1
87	Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy. <i>Seminars in Oncology</i> , 2010 , 37, 468-72	5.5	27
86	Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2163-9	2.2	54
85	IL-2 in the therapy of melanoma and other malignancies. <i>Medical Oncology</i> , 2009 , 26, 23-31	3.7	
84	Inside life of melanoma cell signaling, molecular insights, and therapeutic targets. <i>Current Oncology Reports</i> , 2009 , 11, 405-11	6.3	9
83	CCR9:CCL25 in melanoma metastatic to small intestine. <i>Current Oncology Reports</i> , 2009 , 11, 331-2	6.3	

82	Control of experimental melanoma by host CXCR2. <i>Current Oncology Reports</i> , 2009 , 11, 333-4	6.3	
81	Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 1149-55	3.5	9
80	Summary of the primer on tumor immunology and the biological therapy of cancer. <i>Journal of Translational Medicine</i> , 2009 , 7, 11	8.5	7
79	NCCN clinical practice guidelines in oncology: kidney cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 618-30	7.3	168
78	NCCN clinical practice guidelines in oncology: testicular cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 672-93	7.3	87
77	Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma. <i>Community Oncology</i> , 2008 , 5, 367-374		7
76	Cytokine therapy in cancer. <i>Expert Opinion on Biological Therapy</i> , 2008 , 8, 1495-505	5.4	21
75	Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3743-8	2.2	346
74	Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2292-8	2.2	95
73	State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal <i>Cancer</i> . <i>Cancer</i> , 2008 , 113, 1728-43	6.4	11
72	Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. <i>Cancer</i> , 2008 , 113, 2139-45	6.4	70
71	Melanoma and Other Cutaneous Malignancies 2008 , 2037-2059		
70	Sunitinib efficacy against advanced renal cell carcinoma. <i>Journal of Urology</i> , 2007 , 178, 1883-7	2.5	163
69	A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 549-57	3.5	4
68	Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007 , 133, 705-11	4.9	13
67	Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. <i>Clinical Cancer Research</i> , 2007 , 13, 1232-7	12.9	30
66	An introduction to foundation and industry-sponsored research: practical and ethical considerations. <i>Hematology American Society of Hematology Education Program</i> , 2007 , 2007, 498-503	3.1	3
65	Shortening the infusion time of anticancer drugs: who will benefit?. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2642-3	2.2	1

64	Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. <i>Journal of Clinical Oncology</i> , 2007 , 25, 247-56	2.2	256
63	Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 3312-9	12.9	37
62	Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study. <i>Journal of Immunotherapy</i> , 2007 , 30, 839-46	5	5
61	Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. <i>Journal of Immunotherapy</i> , 2007 , 30, 762-72	5	83
60	Interleukin-2 and Cancer Therapy 2007 , 307-316		1
59	Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. <i>Cancer</i> , 2006 , 106, 2624-9	6.4	31
58	Sunitinib in patients with metastatic renal cell carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 2516-24	27.4	968
57	Interleukin-2 as Cancer Therapy 2006 , 355-364		2
56	A phase II study of depsipeptide in refractory metastatic renal cell cancer. <i>Clinical Genitourinary Cancer</i> , 2006 , 5, 57-60	3.3	130
55	Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 778-85	4.7	33
54	Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 903-11	4.7	23
53	CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. <i>Cancer</i> , 2005 , 104, 1045-8	6.4	219
52	Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. <i>Investigational New Drugs</i> , 2005 , 23, 235-9	4.3	34
51	Management of advanced germ cell cancer in patients with unfavorable prognosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005 , 3, 77-83	7.3	1
50	Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 133-41	2.2	624
49	Mitotic rate and younger age as predictors of sentinel lymph node positivity. <i>Current Oncology Reports</i> , 2005 , 7, 375, 376	6.3	1
48	Molecular staging in stage II and III melanoma patients. <i>Current Oncology Reports</i> , 2005 , 7, 376	6.3	
47	Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1839-48	2.2	49

46	Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. <i>Clinical Cancer Research</i> , 2004 , 10, 461-7	12.9	64
45	Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 54, 241-8	3.5	6
44	Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 54, 283-9	3.5	7
43	A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 54, 331-42	2.5	70
42	CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study.. <i>Blood</i> , 2004 , 104, 810-810	2.2	2
41	Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3133-40	2.2	255
40	Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products. <i>Journal of Clinical Laboratory Analysis</i> , 2003 , 17, 184-94	3	13
39	High dose chemotherapy and stem cell support in the treatment of germ cell cancer. <i>Journal of Urology</i> , 2003 , 169, 1229-33	2.5	10
38	The treatment of brain metastases from malignant melanoma. <i>Seminars in Oncology</i> , 2002 , 29, 518-24	5.5	74
37	Inhibition of vascular endothelial growth factor in the treatment of solid tumors. <i>Current Oncology Reports</i> , 2002 , 4, 20-8	6.3	24
36	Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 353-9	3.5	8
35	Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. <i>Journal of Cancer Research and Clinical Oncology</i> , 2002 , 128, 214-8	4.9	122
34	Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. <i>Journal of Clinical Oncology</i> , 2001 , 19, 851-6	2.2	324
33	Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 47, 327-32	3.5	8
32	Autologous and allogeneic high-dose therapy for melanoma. <i>Current Oncology Reports</i> , 2001 , 3, 338-43	6.3	2
31	Dolastatin-10 in metastatic melanoma: a phase II and pharmacokinetic trial of the California Cancer Consortium. <i>Investigational New Drugs</i> , 2001 , 19, 335-40	4.3	62
30	Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials. <i>Medical Oncology</i> , 2001 , 18, 197-207	3.7	20
29	Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines. <i>Medical Oncology</i> , 2001 , 18, 209-19	3.7	36

28	Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2001 , 7, 284-93	4.7	4
27	Methodologic guidelines for the design of high-dose chemotherapy regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2001 , 7, 414-32	4.7	14
26	Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up. <i>Gynecologic Oncology</i> , 2000 , 77, 433-8	4.9	18
25	Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 46, 19-26	3.5	80
24	A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 46, 403-10	3.5	7
23	Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2000 , 1, 46-54		46
22	Recombinant Human Thrombopoietin in Combination With Granulocyte Colony-Stimulating Factor Enhances Mobilization of Peripheral Blood Progenitor Cells, Increases Peripheral Blood Platelet Concentration, and Accelerates Hematopoietic Recovery Following High-Dose Chemotherapy. <i>Blood</i> , 1999 , 93, 2798-2806	2.2	82
21	Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up. <i>Gynecologic Oncology</i> , 1999 , 75, 419-26	4.9	8
20	Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 1999 , 125, 292-6	4.9	11
19	Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 1999 , 5, 36-45	4.7	18
18	High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2105-16	2.2	1547
17	Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and High-Intermediate Risk Group. <i>Blood</i> , 1997 , 90, 3844-3852	2.2	91
16	Cellular immunotherapy and autologous transplantation for hematologic malignancy. <i>Immunological Reviews</i> , 1997 , 157, 231-40	11.3	42
15	Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. <i>Investigational New Drugs</i> , 1995 , 13, 157-62	4.3	39
14	Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 1995 , 121, 103-6	4.9	31
13	Phase I study of mitomycin C and menadione in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 36, 293-8	3.5	33
12	A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma. <i>Journal of Immunotherapy</i> , 1995 , 18, 52-6	5	17
11	Phase I study of mitomycin C and menadione in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 36, 293-298	3.5	1

10	High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. <i>Cancer</i> , 1994 , 73, 125-34	6.4	25
9	High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team. <i>Cancer</i> , 1994 , 73, 1678-85	6.4	39
8	Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. <i>Cancer Chemotherapy and Pharmacology</i> , 1994 , 35, 161-4	3.5	4
7	Immunotherapy of Colorectal Cancer. <i>BioDrugs</i> , 1994 , 2, 42-52		
6	Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. <i>Journal of Immunotherapy</i> , 1994 , 15, 147-53	5	52
5	High-risk germ cell tumors in men. High response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide. <i>Cancer</i> , 1993 , 71, 2351-7	6.4	7
4	The unique association of malignant histiocytosis and a primary gonadal germ cell tumor. <i>Medical and Pediatric Oncology</i> , 1992 , 20, 162-4		11
3	Treatment of metastatic malignant melanoma with trimetrexate: a phase II study. <i>Medical and Pediatric Oncology</i> , 1990 , 18, 49-52		6
2	High-titer, high-thermal-amplitude cold autoagglutinin not associated with hemolytic anemia. <i>Vox Sanguinis</i> , 1988 , 55, 26-9	3.1	6
1	Hepatic metastasis in granulosa cell tumor of the ovary. <i>Cancer</i> , 1985 , 56, 691-5	6.4	38